Who are Alkem Laboratories's main competitors?

Named competitors: Mankind Pharma (MANKIND.NS), Cipla (CIPLA.NS), Torrent Pharmaceuticals (TORNTPHARM.NS), Lupin (LUPIN.NS). The cockpit's measured peer set (industry) also includes Ionis Pharmaceuticals (IONS), Oruka Therapeutics (ORKA), China Resources Sanjiu Medical & Pharmaceutical (000999.SZ), RemeGen (688331.SS), Gan & Lee Pharmaceuticals (603087.SS), Samsung Epis (0126Z0.KS).

How has Alkem Laboratories stock performed?

Over six months to 6 Nov 2026 the shares returned -5.2% against -0.2% for the median peer; over one year -4.1%.

← CockpitCompetitor Analysis › ALKEM.NS Alkem LaboratoriesOpen in the cockpit ↗

Alkem LaboratoriesALKEM.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Indian branded-generics maker best known for anti-infective drugs, with a growing US generics and biosimilars business.

≈ India's mid-cap generics maker with a biosimilar armMomentum neutral 49

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$6.67B

US dollars, full cap

Free float

37%

of shares outstanding

$/day

$5.66M

20-day average traded

Fwd P/E

27.4×

forward earnings

ROIC−WACC

+1.3 pp

WACC 12.4%

Hurdle

+14 pp

Req g minus delivered

Next earnings

6 days

12 Nov 2026

Close · INR₹5,297

1D+2.1%

1W+3.6%

1M-1.0%

3M-5.4%

6M-5.2%

YTD-3.8%

1Y-4.1%

ATR %2.3%

Beta0.65

52w lowhigh10.7% off high

What Alkem Laboratories does

Indian branded-generics maker best known for anti-infective drugs, with a growing US generics and biosimilars business.

Earns most of its sales from branded medicines in India, sold through a very large field force of representatives to doctors and wholesalers, with anti-infectives and chronic treatments leading. The US generics arm and the biosimilar unit Enzene add exports. The founding Singh family controls it.

In one line: India's mid-cap generics maker with a biosimilar arm.

Products and services

India branded formulations (anti-infectives, Clavam)
US generics
Enzene Biosciences biosimilars
APIs

Customers

Indian retail pharmacies
US distributors

Where it sits in the supply chain

Pharmaceuticals
Branded generics (India)
US generics + biosimilars (Enzene)

What could go right

Domestic anti-infective/chronic brand growth
US generic launches

What could go wrong

Seasonal anti-infective demand swings
US pricing pressure

Moat: narrow (brand, distribution). Leading anti-infective brand (Clavam) and one of India's largest pharma sales forces.

Headquarters: Mumbai, India · Founded: 1973 · Employees: 23,386

Named competitors

Mankind Pharma MANKIND.NS
Cipla CIPLA.NS
Torrent Pharmaceuticals TORNTPHARM.NS
Lupin LUPIN.NS

Alkem Laboratories at a glance

Size Alkem Laboratories (ALKEM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $6.67B, the 170th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹5,297 on 6 Nov 2026.

Performance Over six months the shares fell 5.2%, against -0.2% for the median peer and 0.0% for the India market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 13.4% over the last twelve months (peer median +5.1%); the operating margin is 17.5% (peer median 14.4%).

Valuation It trades at 27.4× forward earnings against a peer median of 20.8× (7th most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.3 points above its cost of capital (12.4% WACC).

Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Alkem Laboratories against the median of its 20 peers (local-currency closes).

Alkem Laboratories financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	₹151B	₹147B	₹129B	₹126B	₹116B
Revenue growth	—	+13%	+3%	+8%	—
Gross profit	₹66.1B	₹57.9B	₹48.4B	₹46.4B	₹37.6B
EBITDA	₹30.3B	₹30.8B	₹25.4B	₹22.5B	₹16.8B
Net income	₹21.6B	₹23.0B	₹21.7B	₹18.0B	₹9.84B
Free cash flow	n/a	₹15.5B	₹15.0B	₹18.4B	₹15.1B
Capital expenditure	n/a	₹6.17B	₹6.76B	₹2.59B	₹2.33B
Total debt	n/a	₹20.5B	₹13.8B	₹14.2B	₹14.0B

Quarterly statements and history in the cockpit →

Alkem Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Alkem Laboratories is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alkem Laboratories is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Alkem Laboratories is the large dot.

Alkem Laboratories competitors and peer comparison

Head to head with its named competitors (ALKEM.NS vs MANKIND.NS vs CIPLA.NS vs TORNTPHARM.NS)
Company	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g
Alkem Laboratories ALKEM.NS	$6.67B	-5%	+13%	17%	27.4×	24.3%
Mankind Pharma MANKIND.NS	$11.1B	+7%	+13%	21%	43.2×	27.6%
Cipla CIPLA.NS	$12.1B	+4%	-1%	13%	29.0×	28.2%
Torrent Pharmaceuticals TORNTPHARM.NS	$19.1B	+9%	+42%	22%	72.2×	37.9%
Lupin LUPIN.NS	$9.65B	-19%	+24%	24%	20.9×	8.8%

How Alkem Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alkem Laboratories against its 20 peers (data as of 6 Nov 2026)
Measure	ALKEM.NS	Peer median	Rank in peer set
1-month return	-1.0%	+2.4%	7th lowest of 21
6-month return	-5.2%	-0.2%	8th lowest of 21
Distance from 52-week high	-10.7%	-14.7%	7th highest of 21
Revenue growth (TTM)	+13.4%	+5.1%	6th highest of 17
Operating margin	17.5%	14.4%	7th highest of 18
Forward P/E	27.4×	20.8×	7th most expensive of 15
Growth the price implies (Req g, 7 yrs)	24.3%	4.8%	2nd most demanding of 11
Growth delivered (Del g)	+10.7%	+10.4%	6th highest of 11
Hurdle (Req g minus delivered)	+13.5 pp	-13.5 pp	2nd most demanding of 11
ROIC minus cost of capital	+1.3 pp	+1.7 pp	9th lowest of 19
EV / EBITDA	20.8×	24.6×	4th cheapest of 9
Net debt / EBITDA	-0.8×	3.7×	4th least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g	Delivered g
Alkem Laboratories ALKEM.NS	India	$6.67B	-5%	+13%	17%	27.4×	24.3%	+10.7%
Ionis Pharmaceuticals IONS	United States	$6.55B	-48%	-7%	-68%	n/a	n/a	n/a
Oruka Therapeutics ORKA	United States	$6.81B	+59%	n/a	n/a	n/a	n/a	n/a
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ	China	$6.48B	0%	+4%	14%	12.8×	-6.3%	+18.4%
RemeGen 688331.SS	China	$6.90B	-26%	+272%	61%	11.9×	2.8%	+303.3%
Gan & Lee Pharmaceuticals 603087.SS	China	$6.40B	+21%	+14%	20%	29.7×	n/a	n/a
Samsung Epis 0126Z0.KS	South Korea	$6.39B	-36%	n/a	-25%	24.0×	n/a	n/a
ONO Pharmaceutical 4528.T	Japan	$7.01B	+2%	-2%	22%	14.7×	-8.2%	+10.8%
Amneal Pharmaceuticals AMRX	United States	$7.01B	+53%	+9%	17%	17.7×	15.2%	+8.7%
Biocon BIOCON.NS	India	$6.28B	-4%	+6%	8%	56.4×	n/a	n/a
Belite Bio, Inc. ADR BLTE	United States	$6.20B	0%	n/a	n/a	n/a	n/a	n/a
Ligand Pharmaceuticals LGND	United States	$6.12B	+38%	+1%	14%	28.0×	57.8%	+7.5%
Mirum Pharmaceuticals MIRM	United States	$6.12B	-13%	+42%	-21%	n/a	n/a	n/a
Huadong Medicine 000963.SZ	China	$7.29B	-17%	+2%	9%	14.0×	-2.7%	+5.3%
Bachem BANB.SW	Switzerland	$7.32B	+3%	+5%	19%	33.1×	n/a	n/a
Kiniksa Pharmaceuticals International KNSA	United States	$7.37B	+60%	+58%	14%	61.7×	9.9%	+45.5%
Cytokinetics CYTK	United States	$7.46B	-30%	-21%	-1,046%	n/a	n/a	n/a
Grifols GRF.MC	Spain	$7.49B	+23%	0%	16%	13.0×	6.8%	+7.1%
Abbott India ABBOTINDIA.NS	India	$5.93B	-1%	+6%	28%	32.4×	11.4%	+10.0%
Shanghai Allist Pharmaceuticals 688578.SS	China	$5.90B	-6%	+39%	47%	13.8×	1.8%	+519.6%
Veradermics MANE	United States	$5.80B	+31%	n/a	n/a	n/a	n/a	n/a

Questions

Who are Alkem Laboratories's main competitors?: Named competitors: Mankind Pharma (MANKIND.NS), Cipla (CIPLA.NS), Torrent Pharmaceuticals (TORNTPHARM.NS), Lupin (LUPIN.NS). The cockpit's measured peer set (industry) also includes Ionis Pharmaceuticals (IONS), Oruka Therapeutics (ORKA), China Resources Sanjiu Medical & Pharmaceutical (000999.SZ), RemeGen (688331.SS), Gan & Lee Pharmaceuticals (603087.SS), Samsung Epis (0126Z0.KS).
Is Alkem Laboratories expensive compared with its peers?: On forward p/e it trades at 27.4× against a peer median of 20.8×, 7th most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Alkem Laboratories stock performed?: Over six months to 6 Nov 2026 the shares returned -5.2% against -0.2% for the median peer; over one year -4.1%.